Thinly traded nano cap PDS Biotechnology (NASDAQ:PDSB) rockets 114% premarket on increased volume in reaction to its plan to develop flu and COVID-19 vaccines based on its Versamune T-cell activating technology.
On another note, it has postponed the start of the Phase 2 VERSATILE-002 study evaluating PDS0101 in head and neck cancer patients due to COVID-19 disruptions.
https://seekingalpha.com/news/3561260-pds-bio-up-114-premarket-on-covidminus-19-vaccine-plan
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.